Die Bedeutung des 5-HT2-Rezeptor-Antagonismus für die Behandlung der Schizophrenie, unter spezieller Berücksichtigung der Minussymptomatik

  • Y. G. Gelders

Zusammenfassung

Die Pharmakotherapie der Psychosen, die durch empirische Ergebnisse mit Chlorpromazin (Delay et al. 1952) eingeleitet wurde, bedeutete eine Revolution auf dem Gebiet der Behandlung nichtorganisch verursachter Geistesstörungen. Haioperidol (Janssen et al. 1959) war ein weiterer Fortschritt auf diesem Gebiet, da sich dieser Stoff als sehr potent und frei von den störenden Nebenwirkungen des Chlorpromazins erwies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ansoms C, De Backer-Dierick G, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone (Dipiperon). Acta Psychiatr Scand 55: 116–122.PubMedCrossRefGoogle Scholar
  2. Auff E, Birkmayer W, Brücke T, Deecke L, Ernich C, Goldenberg G, Hirsch E, Maly J, Müller C, Pötzl G, Riederer P, Sofic E, Schnaberth G (1987) Ritanserin in the treatment of tremor-dominant Parkinson’s disease: A preliminary study. New Trends in Clinical Neuropharmacology 1(3): 149–158.Google Scholar
  3. Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific central serotonin-S2 antagonist. Drug Dev Res 15: 61–73.CrossRefGoogle Scholar
  4. Bersani G, Bressa GM, Meco G, Pozzi F (1990) Mixed D2-and S2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). Hum Psychopharmacol 5: 225–331.CrossRefGoogle Scholar
  5. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40: 492–499.Google Scholar
  6. Bleich A, Brown SL, Kahn R, van Praag H (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297–315.PubMedGoogle Scholar
  7. Bobon J, Collard J, Demaret A (1961) Un nouveau neuroleptique a effet hypnogène differé: le Dipiperon (R 3345), butyrophénone carbamidée. Acta Neurol Psychiatr Belg 61: 611–630.Google Scholar
  8. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Toxicol Pharmacol 20: 140–144.CrossRefGoogle Scholar
  9. Castelao F, Ferreira L, Gelders YG, Heylen SLE (1989) The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr Res 2: 411–415.PubMedCrossRefGoogle Scholar
  10. Claus A (1990) Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a multicenter double-blind comparative study. Janssen Research Foundation, May 1990; Clinical Research Report RIS-BEL-6.Google Scholar
  11. Crow TJ (1985) The two syndrome concept: origins and current status. Schizophr Bull 11: 471–486.PubMedGoogle Scholar
  12. Crow TJ (1987) The dopamine hypothesis survives, but there must be a way ahead. Br J Psychiatry 151: 460–465.PubMedCrossRefGoogle Scholar
  13. Deberdt R (1976) Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large scale multicentre evaluation. Acta Psychiatr Belg 76: 157–166.PubMedGoogle Scholar
  14. Declerck AC, Wauquier A, Van Der Ham-Veltman PHM, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin-S2 antagonist ritanserin. Curr Ther Res 41: 427–432.Google Scholar
  15. Delay J, Deniker P, Harl J, Grasset A (1952) Traitement d’états confusionnels par le chlorhydrate de diméthylaminopropyl-N-chlorphénothiazine (4560 RP). Ann Med Psychol 110: 398–403.Google Scholar
  16. DeLisi LE, Freed WI, Gillin JC, Kleinman JE, Bigelow LB, Wyatt RJ (1982) p-Chloro-phenylalanine trial in schizophrenic patients. Biol Psychiatry 17: 471–477.PubMedGoogle Scholar
  17. DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ (1981) Increased whole blood serotonin concentrations in chronic schizophrenic patients. Arch Gen Psychiatry 38: 647–650.PubMedCrossRefGoogle Scholar
  18. Desseilles M, Antoine J, Pietquin M, Burton P, Gelders Y, Heylen S (1990) Risperidone (R 64 766) in the treatment of therapy-resistant chronic psychotic patients: an open dose-finding study. Psychiatr Psychobiol (im Druck).Google Scholar
  19. Fink H, Morgenstern R, Oelssmer W (1984) Clozapine, a serotonin antagonist. Pharmacol Biochem Behav 20: 513–517.PubMedCrossRefGoogle Scholar
  20. Gelders YG, Heylen SLE, Van den Bussche G, Reyntjens AJM, Janssen PAJ (1990) Pilot clinical investigation of risperidone in the treatment of psychotic patients. Pharmacopsychiatry 23: 206–211.PubMedCrossRefGoogle Scholar
  21. Gillin JC, Kaplan J, Wyatt RJ (1976) Clinical effects of tryptophan in chronic schizophrenia. Biol Psychiatry 11: 635–639.PubMedGoogle Scholar
  22. Gross H, Langner E (1966) Das Wirkungsprofil eines chemisch neuartigen Breitbandneuroleptikums der Dibenzodiazepingruppe. Wien Med Wochenschr 116: 614.Google Scholar
  23. Heylen SLE, Gelders YG (1989) Risperidone versus haloperidol in the treatment of psychotic patients: an 8 week multicentre double-blind comparative trial. In: International Symposium on Serotonin, From Cell Biology to Pharmacology and Therapeutics, Florence 1989, Abstract Book, p 93.Google Scholar
  24. Hyttel J, Larssen JJ, Christensen AV, Arnt J (1985) Receptor binding profiles of neuroleptics. In: Casey DE (ed): Dyskinesia: Research and treatment. Springer, Berlin Heidelberg New York Tokyo, pp 9–18.CrossRefGoogle Scholar
  25. Idzikowski C, Mills EJ, Glennard R (1986) 5-Hydroxytryptamine-2 antagonist increases human slow wave sleep. Brain Res 378: 164–168.PubMedCrossRefGoogle Scholar
  26. Janssen PAJ (1987) Does ritanserin, a potent serotonin-S2 antagonist, restore energetic functions during the night. R Soc Med 80: 409–413.Google Scholar
  27. Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693.PubMedGoogle Scholar
  28. Janssen PAJ, van de Westeringh C, Jagenau AHM et al. (1959) Chemistry and pharmacology of CNS depressants related to 4-(4-hydroxy-4-phenylpiperidino)-butyrophenone. Part I: Synthesis and screening data in mice. J Med Pharmaceut Chem 1: 281–287.CrossRefGoogle Scholar
  29. Kane J, Honigfeld G, Singer J et al. (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796.PubMedCrossRefGoogle Scholar
  30. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndromes scale (PANSS) for schizophrenics: development and standardization. Schizophr Bull 13: 261–276.PubMedGoogle Scholar
  31. Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Res 23: 99–110.PubMedCrossRefGoogle Scholar
  32. Lambert PA, Bouchardy M, Marcou G, Gradel F (1969) Principales indications du pipampérone. Compte Rendu Congrès Psychiatrique et Neurologique de Langue Française, LXVIIe session, Bruxelles, Septembre 1969.Google Scholar
  33. Leysen JE, Gommeren W, van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin. A potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611.PubMedGoogle Scholar
  34. Leysen JE, Gommeren W, Eens A, De Chaffoy De Courcelles D, Stoof JC, Janssen PAJ (1988) The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661–670.PubMedGoogle Scholar
  35. Maisch U (1987) Behandlung von Schlafstörungen bei älteren Patienten. Ergebnisse einer Doppelblindstudie Pipamperon vs. ein Standardbenzodiazepinpräparat. Therapiewoche 37: 2484–2487.Google Scholar
  36. Meert TF, De Haes P, Janssen PAJ (1989a). Risperidone (R 64 766) a potent and complete LSD antagonist in drug discrimination by rats. Psychopharmacology 97: 206–212.PubMedCrossRefGoogle Scholar
  37. Megens AAHP, Awouters FHL, Niemegeers CJE (1988) Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol. Psychopharmacology 95: 493–496.PubMedCrossRefGoogle Scholar
  38. Megens AAHP, Awouters FHL, Niemegeers CJE (1989) Interaction of haloperidol and risperidone (R 64 766) with amphetamine-induced motility changes in rats. Drug Dev Res 17: 23–33.CrossRefGoogle Scholar
  39. Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2: 19–76.PubMedGoogle Scholar
  40. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC (1979) Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 45: 165–175.PubMedCrossRefGoogle Scholar
  41. Mendels J (1967) The effect of methysergide (an antiserotonin agent) on schizophrenia: A preliminary report. Br J Psychiatry 124: 157–160.Google Scholar
  42. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R 64 766) in psychotic patients. Psychopharmacology 99: 445–449.PubMedCrossRefGoogle Scholar
  43. Möller H-J, Pelzer E, Kissling W, Riehl T, Wernicke T (1990, eingereicht) Efficacy and tolerability of a new antipsychotic compound (Risperidone): Results of an open pilot-study Pharmacopsychiatry.Google Scholar
  44. Montfort J-C, Bourguignon A, Manus A, Bouhours P, Heylen S (1990) Open study of risperidone in the treatment of schizophrenic patients with predominant negative symptoms. Janssen Research Foundation, January 1990; Clinical Research Report R 64766/24.Google Scholar
  45. Molander L, Borgström L (1983) Sedative effects and prolactin response to single oral doses of melperone. Psychopharmacology 79: 142–147.PubMedCrossRefGoogle Scholar
  46. Niemegeers CJE (1990) Serotonin involvement in the action of antipsychotic drugs. In: Paoletti R et al. (eds) Serotonin: from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht, The Netherlands, pp 531–541.Google Scholar
  47. Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects at brain dopamine, serotonin, adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137: 1518–1522.PubMedGoogle Scholar
  48. Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Vanden Bussche G (1986) Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res 8: 205–211.CrossRefGoogle Scholar
  49. Richelson E (1980) Neuroleptics and neurotransmitter receptors. Psychiatr Ann 10: 21–26.Google Scholar
  50. Richelson E (1984) Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 45: 331–336.PubMedGoogle Scholar
  51. Roose K, Gelders Y, Heylen S (1988) Risperidone (R 64 766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiat Belg 88: 233–241.Google Scholar
  52. Shore D, Korpi ER, Bigelmow LB, Zec RF, Wyatt RJ (1985), Fenfluramine and chronic schizophrenia. Biol Psychiatry 20: 349–352.PubMedCrossRefGoogle Scholar
  53. Vinar O, Molcan J, Nahunek K, Svestka J, Zaplek M et al (1989) Ritanserin in schizophrenic patients. Activ Nerv Super 31(2): 107–109.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Y. G. Gelders

There are no affiliations available

Personalised recommendations